This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ONCT Oncternal Therapeutics (ONCT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About Oncternal Therapeutics Stock (NASDAQ:ONCT) Get Oncternal Therapeutics alerts:Sign Up Key Stats Today's Range$0.53▼$0.5350-Day Range$0.53▼$0.5352-Week Range$0.53▼$7.17VolumeN/AAverage Volume99,758 shsMarket Capitalization$1.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. Read More Receive ONCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCT Stock News HeadlinesOncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its OperationsJuly 1, 2025 | globenewswire.comChronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 17, 2025 | theglobeandmail.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.August 14 at 1:00 AM | Stansberry Research (Ad)Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 21, 2025 | theglobeandmail.comOncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SECMarch 7, 2025 | globenewswire.comOncternal Therapeutics (NASDAQ:ONCT) Stock, Short Interest ReportNovember 26, 2024 | benzinga.comOncternal Therapeutics Reports Q3 2024 EarningsNovember 21, 2024 | markets.businessinsider.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comSee More Headlines ONCT Stock Analysis - Frequently Asked Questions How were Oncternal Therapeutics' earnings last quarter? Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($2.89) earnings per share for the quarter, topping analysts' consensus estimates of ($3.03) by $0.14. The company had revenue of $0.80 million for the quarter, compared to analysts' expectations of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,599.95% and a negative trailing twelve-month return on equity of 177.58%. Read the conference call transcript. When did Oncternal Therapeutics' stock split? Oncternal Therapeutics's stock reverse split on the morning of Monday, January 8th 2024.The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Oncternal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include NIO (NIO), Walt Disney (DIS), Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings8/08/2024Today8/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ONCT CIK1260990 Webwww.oncternal.com Phone(858) 434-1113Fax901-844-8075Employees30Year Founded1997Profitability EPS (Trailing Twelve Months)($11.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.48 million Net Margins-1,599.95% Pretax Margin-1,599.95% Return on Equity-177.58% Return on Assets-131.30% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual Sales$790 thousand Price / Sales1.97 Cash FlowN/A Price / Cash FlowN/A Book Value$10.19 per share Price / Book0.05Miscellaneous Outstanding Shares2,960,000Free Float2,628,000Market Cap$1.56 million OptionableNo Data Beta1.18 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:ONCT) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defe...Decentralized Masters | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
